{"product_id":"phytomenadione-konakion-mm-10-mg-solution-10","title":"Phytomenadione, KONAKION MM 10 mg solution 10","description":"\u003ch1\u003eKONAKION MM, \u003cspan data-mce-fragment=\"1\"\u003ePhytomenadione\u003c\/span\u003e 10 mg solution\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003ePack size:\u003c\/span\u003e\u003cspan\u003e10 \u003c\/span\u003e\u003cspan\u003epieces\u003c\/span\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003cspan\u003eSolution\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKonakion® MM 10mg ampoules\u003cbr\u003eActive ingredient: Phytomenadione\u003cbr\u003eApplication:\u003cbr\u003eTherapy of vitamin K deficiency bleeding and prevention of Vit. K deficiency states that cannot be remedied through nutrition: Vit. K prophylaxis by administering Vit. K to pregnant women before pregnancy. Childbirth if you take anticonvulsants and tuberculostatics or coumarin derivatives. had taken. Vitamin K prophylaxis in patients with risk factors for the development of a vitamin K deficiency as soon as d. Quick W. below (or INR above) d. Normal limit is measured. Vit.-K therapy in patients with Vit.-K deficiency bleeding, with a Quick-W. below 10% (or INR over 6).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor the treatment of vitamin K deficiency bleeding and the prevention of vitamin K deficiency states.\u003c\/span\u003e\u003c\/p\u003e\n\u003csection class=\"text-primary-max-dark\"\u003e\n\u003ch3 class=\"text-s font-medium\"\u003e\u003cspan\u003eActive ingredients\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul class=\"mb-3.5 list-disc pl-5 text-s\"\u003e\n\u003cli\u003e\u003cspan\u003e10 mg phytomenadione\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/section\u003e\n\u003csection class=\"text-primary-max-dark\"\u003e\n\u003ch3 class=\"text-s font-medium\"\u003e\u003cspan\u003eExcipients\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul class=\"mb-3.5 list-disc pl-5 text-s\"\u003e\n\u003cli\u003e\u003cspan\u003eWater for injections\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLecithin (soybean)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSodium hydroxide for pH adjustment\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHydrochloric acid for pH adjustment\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eGlycocholic acid\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eIndication \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eThe medicine is a vitamin used to prevent bleeding (anti-hemorrhagic).\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe only proven area of ​​application is the treatment of vitamin K deficiency bleeding and the prevention of vitamin K deficiency states that cannot be remedied through nutrition.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eThis includes:\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eProphylaxis of vitamin K deficiency for the newborn by giving vitamin K to the pregnant woman before delivery if she has taken anticonvulsants, tuberculostatics or coumarin derivatives.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eProphylaxis of vitamin K deficiency in patients with risk factors for developing vitamin K deficiency as soon as the INR rises above the normal limit.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eVitamin K therapy in patients with vitamin K deficiency bleeding, which is usually associated with an INR \u0026gt;\/= 5. Vitamin K deficiency bleeding can be caused by a true vitamin K deficiency or by too high a dosage of coumarin derivatives.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eDosage \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eAlways use this medicine exactly as described or exactly as discussed with your doctor, pharmacist or nurse. If you are unsure, ask your doctor, pharmacist or nurse.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe following information applies unless your doctor has prescribed otherwise.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003ePrevention of vitamin K deficiency\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eFor pregnant women taking anticonvulsants or antituberculostatic drugs:\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003e10 to 20 mg vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e (1 to 2 ml) orally 48 hours to a few hours before delivery.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K treatment\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eIn the case of severe or life-threatening vitamin K deficiency bleeding (e.g. during anticoagulant therapy), vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e must be administered slowly (at least 30 seconds) intravenously in a dosage of 5 to 10 mg (1 ampoule contains 10 mg of vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e ) together with fresh frozen plasma or a prothrombin complex preparation (30 U\/kg). The vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e dose can be repeated as needed.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eDosage recommendations for vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e therapy in patients with asymptomatic high INR with or without minor bleeding\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Phenprocoumon\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eINR: 5 - 9\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: 2.0 to 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 2.0 to 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eINR: \u0026gt;9\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: 2.0 to 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 2.0 to 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cspan\u003eINR: \u0026gt; 10\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: not recommended\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e , intravenous: Individual dosage adjustment\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Warfarin\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eINR: 5 - 9\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e , oral: 1.0 to 2.5 mg for initial reversal; 2.0 to 5.0 mg for rapid reversal; (additional 1.0 to 2.0 mg if INR is still elevated after 24 hours)\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 0.5 to 1.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cspan\u003eINR: \u0026gt;9\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: 2.5 to 5.0 mg (up to 10.0 mg)\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 1.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Acenocoumarol\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eINR: 5 - 8\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: 1.0 to 2.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 1.0 to 2.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cspan\u003eINR: \u0026gt; 8\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e oral: 3.0 to 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 1.0 to 2.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFor low doses, one or more 2 mg ampoules (2 mg\/0.2 ml, same solution) may be used.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eDosage recommendations for vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e therapy in patients with severe and life-threatening bleeding\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Phenprocoumon\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eCondition: severe bleeding, INR \u0026lt; 5.0\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAdjunctive therapy: PCC\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eCondition: severe bleeding, INR \u0026gt; 5.0\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 10.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAdjunctive therapy: PCC\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Warfarin\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eCondition: severe bleeding\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 5.0 to 10.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAdjunctive therapy: FFP or PCC\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eCondition: life-threatening bleeding\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 10.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eConcomitant therapy: FFP, PCC or recombinant factor VIIa\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eAnticoagulant: Acenocoumarol\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eCondition: severe bleeding\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eVitamin K1 \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e,\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e intravenously: 5.0 mg\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eConcomitant therapy: FFP, PCC or prothrombin concentrates and factor VII\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFFP: fresh frozen plasma\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePCC: Prothrombin complex concentrate\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eIn patients with absorption disorders:\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eParenteral use is recommended for patients with absorption disorders (e.g. insufficient absorption of food components from the digestive tract [malabsorption], short bowel syndrome, pancreatic disease), with the dosage corresponding to oral use. If the INR value does not drop sufficiently to approx. 2 within 3 to 6 hours or the bleeding does not stop, a second, possibly larger dose of vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e should be given.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eElderly patients\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eOlder patients tend to be more sensitive to anticoagulant reversal with the drug. For these patients, the dosage should be in the lower range of the recommendation.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eSmall doses of 0.5 to 1.0 mg of vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e , administered intravenously or orally, show an effective decrease in INR to \u0026lt; 5.0 within 24 hours.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eChildren over 1 year old\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eThe optimal dosage should be determined by the attending physician based on the indications and the child's weight. A single dose of 1\/10 of the adult intravenous Viramin-K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e dose resulted in effective reversal of the asymptomatic high (\u0026gt;8) INR in clinically healthy children.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePlease talk to your doctor or pharmacist if you have the impression that the effect is too strong or too weak.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eIf you have used more than you should\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eEven after massive overdose, no toxic symptoms have been reported so far. Resumption of anticoagulation may be impaired.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eIf you have any further questions about the use of this medicine, talk to your doctor, pharmacist or nurse.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eWay \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eThe medicine can be administered orally or intravenously.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eFor oral administration, the required amount (1 mg vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e corresponds to 0.1 ml solution) must be taken from the ampoule using a syringe with an attached cannula, remove the cannula from the syringe and pour the contents of the syringe directly into the patient's mouth apply. You should then drink more liquid.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eBecause of the glycocholic acid content, the drug must not be used parenterally in cases of jaundice with bile stasis (cholestatic jaundice). To treat the risk of bleeding due to vitamin K deficiency in severe liver dysfunction, the preparation should be administered orally.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe medicine must not be injected intramuscularly in patients with an increased tendency to bleeding.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eSide effects \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eLike all medicines, this medicine can cause side effects, although not everyone gets them.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eThe frequency information on side effects is based on the following categories:\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eVery common: more than 1 patient in 10\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eCommon: 1 to 10 treated in 100\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eUncommon: 1 to 10 people treated in 1,000\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eRare: 1 to 10 people treated in 10,000\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eVery rare: less than 1 person treated in 10,000 people treated\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNot known: Frequency cannot be estimated from the available data\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eDiseases of the immune system\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eVery rare: Anaphylactic reactions after intravenous administration.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eGeneral disorders and administration site conditions\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eVery rare: Venous irritation or inflammation of the veins (phlebitis) associated with intravenous administration of the drug.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eIf you notice any side effects, contact your doctor, pharmacist or nurse. This also applies to side effects that are not specified.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eInteractions \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eUse with other medicines\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eTell your doctor or pharmacist if you are taking\/using any other medicines, have recently taken\/used any other medicines or might take\/use any other medicines.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eCoumarin derivatives, like cephalosporins with an N-methyl-thiotetrazole group, inhibit the epoxide reductase in the vitamin K cycle and thus the cofactor function of vitamin K \u003c\/span\u003e\u003csub\u003e\u003cspan\u003e1\u003c\/span\u003e\u003c\/sub\u003e\u003cspan\u003e in the carboxylation reaction.\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAcetylsalicylic acid and other salicylates also reduce the effect of vitamin K by inhibiting the carboxylase-reductase system.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eCephalosporins with the N-methyl-thiotetrazole group inhibit vitamin K epoxide reductase and thus the vitamin K effect.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAnticonvulsants such as phenobarbital and diphenylhydantoin, as well as the tuberculostatic drugs INH and rifampicin, can cause vitamin K deficiency bleeding on the first day of life in newborns whose mothers took these drugs during pregnancy. The exact mechanism is still unclear.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eWhen anticoagulants (coumarin-type anticoagulants) are used, vitamin K prevents their therapeutic effect and thus creates a risk of thrombosis.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003eContraindications \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eThe medicine must not be used\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eif you are allergic to phytomenadione (vitamin K1) or any of the other ingredients of this medicine\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ein newborns; A different potency is available to prevent neonator haemorrhagic disease.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003ePregnancy and breast feeding period \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003ch5 class=\"mb-2.5 text-m font-medium\"\u003e\n\u003cspan\u003ePatient information \u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e\n\u003c\/h5\u003e\n\u003cdiv class=\"prose mb-3.5 whitespace-normal text-s last:mb-0\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eWarnings and Precautions\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003ePlease talk to your doctor, pharmacist or nurse before using the medicine. Because of the glycocholic acid content, the preparation must not be used parenterally in cases of jaundice with bile stasis (cholestatic jaundice). To treat the risk of bleeding due to vitamin K deficiency in severe liver dysfunction, the drug should be administered orally. Careful monitoring of the INR value is necessary in these patients.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eThe drug must not be injected intramuscularly in patients with an elevated INR value due to the risk of extensive hematomas.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eIf you are undergoing anticoagulant treatment with coumarin derivatives and the aim is to reverse this effect, it must be borne in mind that the renewed ability of the blood to clot can cause the risk of thrombosis, i.e. the risk of vascular occlusion, to arise again and possibly even to increase. Therefore, self-treatment is very dangerous and should be avoided. If you monitor your coagulation through self-management, you should always consult your doctor if you have an elevated INR value of \u0026gt;\/= 5.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eNewborns and children under 1 year old\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eThe medicine must not be given to newborns and children under 1 year of age. The preparation should be used for these patient groups.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan\u003eAbility to drive and use machines\u003c\/span\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eThere are no known effects on the ability to drive or use machines.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan\u003ePhytomenadione, KONAKION MM 10 mg solution\u003c\/span\u003e\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"CHEPLAPHARM Arzneimittel GmbH","offers":[{"title":"Default Title","offer_id":54925548683641,"sku":"04273031","price":138.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0903\/0792\/0249\/files\/Phytomenadione_KONAKIONMM10mgsolution.jpg?v=1738701568","url":"https:\/\/ukdorf.co.uk\/products\/phytomenadione-konakion-mm-10-mg-solution-10","provider":"UKDorf (ELIVERA) Buy online, Reviews Est. 1988 London, UK.","version":"1.0","type":"link"}